Our laboratory has demonstrated that treatment with recombinant IL-1 receptor antagonist (IL-1ra) by repeated injections markedly suppresses inflammation and tissue damage in experimental colitis. In addition, we have recently shown that patients with ulcerative colitis and Crohn's disease have a decreased intestinal IL-1ra/IL-1 ratio compared to normal controls and self-limited infectious colitis, suggesting that patients with inflammatory bowel disease may have a deficit in their ability to produce IL-1ra. Therefore, restoration of the physiological balance between IL-1ra and IL-1 may prove beneficial in reducing intestinal inflammation. Our hypothesis is that development of a cellular transplantation system that can stably produce and deliver recombinant IL-1ra into the systemic circulation may represent an important advance in our ability to treat inflammatory disease, including inflammatory bowel disease and liver diseases in which IL-1 have been shown to play an important role. This hypothesis will be investigated by accomplishing the following specific aims: 1) construct plasmid vectors containing either the secreted(s) or the intracellular (ic) form of rabbit IL-1ra cDNA, and produce stably transfected myogenic cell lines or primary cultured myoblasts synthesizing large amounts of recombinant IL-1ra in vitro; 2) inject intramuscularly, cultured myoblasts that will fuse into adjacent normal muscle fibers and will deliver large amounts of secreted IL-1ra in vivo. These studies will employ state-of-the art molecular biology techniques combined with validated immunoassay methodology. The ultimate goal of this proposal is to apply information derived from these studies to treat and prevent liver and gastrointestinal inflammatory diseases through augmentation of IL-1ra expression by utilizing gene therapy methodologies.

Project Start
1999-05-01
Project End
2000-02-29
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Chang, Huiyi H; Yeh, Jih-Chao; Ichiyama, Ronaldo M et al. (2018) Mapping and neuromodulation of lower urinary tract function using spinal cord stimulation in female rats. Exp Neurol 305:26-32
Chen, Chien-Yu; Chen, Jingyu; He, Lina et al. (2018) PTEN: Tumor Suppressor and Metabolic Regulator. Front Endocrinol (Lausanne) 9:338
Nakamura, Brooke N; Glazier, Alison; Kattah, Michael G et al. (2018) A20 regulates canonical wnt-signaling through an interaction with RIPK4. PLoS One 13:e0195893
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Wu, Raymond; Murali, Ramachandran; Kabe, Yasuaki et al. (2018) Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. Hepatology 68:1726-1740
Ogasawara, Noriko; Poposki, Julie A; Klingler, Aiko I et al. (2018) IL-10, TGF-?, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells. J Allergy Clin Immunol 141:1147-1151.e8
Edman, Maria C; Janga, Srikanth R; Meng, Zhen et al. (2018) Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients. Sci Rep 8:11044
Baulies, Anna; Montero, Joan; Matías, Nuria et al. (2018) The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading. Redox Biol 14:164-177
Ju, Yaping; Janga, Srikanth Reddy; Klinngam, Wannita et al. (2018) NOD and NOR mice exhibit comparable development of lacrimal gland secretory dysfunction but NOD mice have more severe autoimmune dacryoadenitis. Exp Eye Res 176:243-251
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184

Showing the most recent 10 out of 449 publications